- New
GLOW Blend 70 mg · Lyophilised vial
50 mg GHK-Cu · 10 mg TB-500 · 10 mg BPC-157 in one vial.
High-strength retatrutide vial for extended titration.
High-strength retatrutide vial for extended titration. Active: Retatrutide. Strength: 20 mg. Form: Lyophilised vial. Route: Subcutaneous. Class: Triple agonist. Supplied under the Hexal-OZ line. Priced in AUD; paid in crypto via BTCPay (XMR preferred, BTC secondary).
Data sheet
50 mg GHK-Cu · 10 mg TB-500 · 10 mg BPC-157 in one vial.
Injectable ERR agonist — exercise-mimetic research.
Nerve repair and anti-inflammatory research peptide.
GHRH analog targeting visceral fat and GH output.
Systemic recovery and flexibility. Pairs with BPC-157.
Mitochondrial peptide for metabolism and endurance.
Skin, collagen and wound-healing copper peptide.
Long-arginine IGF-1 for local growth and recovery.
Mitochondria-targeted recovery and longevity peptide.
Sleep-quality and recovery research peptide.
Higher-strength MOTS-c for extended protocols.
GLP-1/GIP dual agonist for appetite and glucose.
Pre-filled retatrutide pen — GLP-1/GIP/glucagon.
Anti-inflammatory and gut-health tripeptide.